Stock comparison
BioAge Labs
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIOA
BioAge Labs
Market cap
$625.36M
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIOA | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 42D | 70B | HAE |
| Benjamin Graham | 42D | 85A | HAE |
| Philip Fisher | 65C | 60C | BIOA |
| Peter Lynch | 4F | 54C | HAE |
| Joel Greenblatt | 4F | 31F | HAE |
| Charlie Munger | 61D | 54D | BIOA |
| Terry Smith | 64D | 55D | BIOA |
Side-by-side metrics
| Metric | BIOA | HAE |
|---|---|---|
| Market cap | $625.36M | $2.98B |
| P/E (TTM) | - | 24.8x |
| EV/EBIT | - | 14.1x |
| ROIC (TTM) | -26.51% | 8.37% |
| Gross margin | 99.39% | 55.74% |
| Net margin | -8.72% | 7.29% |
| Revenue CAGR 5y | - | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | 0.0x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIOA leads on
- P/E (TTM)-vs 24.8x+131%
- EV/EBIT-vs 14.1x+129%
- Debt / Equity0.0xvs 1.5x+99%
- Gross margin99.39%vs 55.74%+44%
HAE leads on
- ROIC (TTM)8.37%vs -26.51%+132%
- Net margin7.29%vs -8.72%+101%
- Market cap$2.98Bvs $625.36M+79%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.